H.R.10887

Protecting Consumer Access to Generic Drugs Act of 2026 prohibits brand name drug and biological product manufacturers from compensating generic and.

The Protecting Consumer Access to Generic Drugs Act of 2026 aims to prevent brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of generic drugs into the market. It also prohibits biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay their entry. The act makes it unlawful for these entities to enter into agreements that resolve or settle patent infringement claims if they involve compensation that limits or delays market entry.